Personalized medicine and type 2 diabetes: Lesson from epigenetics

Epigenomics

Volumn 6, Issue 2, 2014, Pages 229-238

  Raciti, Gregory Alexander ^a   Nigro, Cecilia ^a   Longo, Michele ^a   Parrillo, Luca ^a   Miele, Claudia ^a   Formisano, Pietro ^a   Béguinot, Francesco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

epigenetics; histone modifications; methylation; miRNA; personalized medicine; Type 2 diabetes

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; HISTONE;

ADIPOGENESIS; ALLELE; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CHROMATIN; CHROMATIN CONDENSATION; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; CPG ISLAND; DNA FINGERPRINTING; DNA METHYLATION; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; FAT INTAKE; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE SWITCHING; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE TOLERANCE; HEREDITY; HISTONE MODIFICATION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE; LIFESTYLE; LIPID METABOLISM; LIPID STORAGE; MALNUTRITION; METABOLIC DISORDER; MONOZYGOTIC TWINS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PANCREAS ISLET; PATHOGENESIS; PERSONALIZED MEDICINE; PHARMACOKINETICS; PHENOTYPE; PHYSICAL ACTIVITY; PLASTICITY; PREGNANCY; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN RESTRICTION; REVIEW; SILENT GENE; SKELETAL MUSCLE; SMOKING; SPERMATOGENESIS; SUBCUTANEOUS FAT; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; GENETIC EPIGENESIS; METABOLISM;

DIABETES MELLITUS, TYPE 2; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE;

EID: 84900431394     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.10     Document Type: Review

References (95)

1. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378(9786), 169-181 (2011).
2. International Diabetes Federation. Diabetes Atlas (5th Edition) (2012).www.idf.org/sites/default/files/5E-IDFAtlasPoster-2012-EN.pdf
3. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in Type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J. Clin. Endocrinol. Metab. 95(4), 1566-1574 (2010).
4. Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin. Chem. 57(2), 231-240 (2011).
5. Drong AW, Lindgren CM, McCarthy MI. The genetic and epigenetic basis of Type 2 diabetes and obesity. Clin. Pharmacol. Ther. 92(6), 707-715 (2012).
6. Travers ME, McCarthy MI. Type 2 diabetes and obesity: genomics and the clinic. Hum. Genet. 130(1), 41-58 (2011).
7. Prudente S, Dallapiccola B, Pellegrini F, Doria A, Trischitta V. Genetic prediction of common diseases. Still no help for the clinical diabetologist! Nutr. Metab. Cardiovasc. Dis. 22(11), 929-936 (2012).
8. Kirchner H, Osler ME, Krook A, Zierath JR. Epigenetic flexibility in metabolic regulation: disease cause and prevention? Trends Cell Biol. 23(5), 203-209 (2013).
9. Schwenk RW, Vogel H, Schürmann A. Genetic and epigenetic control of metabolic health. Mol. Metab. 2(4), 337-347 (2013).
10. Ungaro P, Mirra P, Oriente F et al. Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1. J. Biol. Chem. 287(51), 42951-42961 (2012).
11. Ungaro P, Teperino R, Mirra P et al. Molecular cloning and characterization of the human PED/PEA-15 gene promoter reveal antagonistic regulation by hepatocyte nuclear factor 4alpha and chicken ovalbumin upstream promoter transcription factor II. J. Biol. Chem. 283(45), 30970-30979 (2008).
12. Oriente F, Fernandez Diaz LC, Miele C et al. Prep1 deficiency induces protection from diabetes and increased insulin sensitivity through a p160-mediated mechanism. Mol. Cell. Biol. 28(18), 5634-5645 (2008).
13. Oriente F, Iovino S, Cabaro S et al. Prep1 controls insulin glucoregulatory function in liver by transcriptional targeting of SHP1 tyrosine phosphatase. Diabetes 60(1), 138-147 (2011).
14. Oriente F, Cabaro S, Liotti A et al. PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice. Diabetologia 56(12), 2713-2722 (2013).
15. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol. Sci. 100(1), 7-23 (2007). (Pubitemid 47617798)
16. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ. Res. 107(12), 1403-1413 (2010).
17. Paneni F, Costantino S, Volpe M, Lüscher TF, Cosentino F. Epigenetic signatures and vascular risk in Type 2 diabetes: a clinical perspective. Atherosclerosis 230(2), 191-197 (2013).
18. Ng SF, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ. Chronic high-fat diet in fathers programs β-cell dysfunction in female rat offspring. Nature 467(7318), 963-966 (2010).
19. Toperoff G, Aran D, Kark JD et al. Genome-wide survey reveals predisposing diabetes Type 2-related DNA methylation variations in human peripheral blood. Hum. Mol. Genet. 21(2), 371-383 (2012).
20. Korber P, Becker PB. Nucleosome dynamics and epigenetic stability. Essays Biochem. 48(1), 63-74 (2010).
21. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13(7), 484-492 (2012).
22. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol. Cell. Biol. 22(9), 3157-3173 (2002). (Pubitemid 34437474)
23. Fukuda H, Sano N, Muto S, Horikoshi M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief. Funct. Genomic Proteomic. 5(3), 190-208 (2006). (Pubitemid 46470220)
24. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12(5), 599-606 (1998). (Pubitemid 28134293)
25. McGee SL, Sparling D, Olson AL, Hargreaves M. Exercise increases MEF2-and GEF DNA-binding activity in human skeletal muscle. FASEB J. 20(2), 348-349 (2006). (Pubitemid 46671167)
26. Yu M, Blomstrand E, Chibalin AV, Krook A, Zierath JR. Marathon running increases ERK1/2 and p38 MAP kinase signalling to downstream targets in human skeletal muscle. J. Physiol. 536(Pt 1), 273-282 (2001). (Pubitemid 32952236)
27. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem. Cell. Biol. 41(1), 87-95 (2009).
28. Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 7(4), 147-154 (2009).
29. Hammoud SS, Nix DA, Zhang H, Purwar J, Carrell DT, Cairns BR. Distinctive chromatin in human sperm packages genes for embryo development. Nature 460(7254), 473-478 (2009).
30. Dunn GA, Bale TL. Maternal high-fat diet effects on third-generation female body size via the paternal lineage. Endocrinology 152(6), 2228-2236 (2011).
31. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. Diabetes 61(2), 542-546 (2012).
32. Ling C, Del Guerra S, Lupi R et al. Epigenetic regulation of PPARGC1A in human Type 2 diabetic islets and effect on insulin secretion. Diabetologia 51(4), 615-622 (2008).
33. Yang BT, Dayeh TA, Kirkpatrick CL et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia 54(2), 360-367 (2011).
34. Volkmar M, Dedeurwaerder S, Cunha DA et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from Type 2 diabetic patients. EMBO J. 31(6), 1405-1426 (2012).
35. Bell CG, Finer S, Lindgren CM et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO Type 2 diabetes and obesity susceptibility locus. PLoS ONE 5(11), e14040 (2010).
36. Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Restricted adipogenesis in hypertrophic obesity: the role of WISP2, WNT, and BMP4. Diabetes 62(9), 2997-3004 (2013).
37. Musri MM, Gomis R, Párrizas M. A chromatin perspective of adipogenesis. Organogenesis 6(1), 15-23 (2010).
38. Pinnick KE, Karpe F. DNA methylation of genes in adipose tissue. Proc. Nutr. Soc. 70(1), 57-63 (2011).
39. Kong L, Zhu J, Han W et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed Type 2 diabetes: a clinical study. Acta Diabetol. (1), 61-69 (2011).
40. Rosero S, Bravo-Egana V, Jiang Z et al. MicroRNA signature of the human developing pancreas. BMC Genomics 11, 509 (2010).
41. Muhonen P, Holthofer H. Epigenetic and microRNA-mediated regulation in diabetes. Nephrol. Dial. Transplant. 24(4), 1088-1096 (2009).
42. Correa-Medina M, Bravo-Egana V, Rosero S et al. MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr. Patterns 9(4), 193-199 (2009).
43. Ramachandran D, Roy U, Garg S, Ghosh S, Pathak S, Kolthur-Seetharam U. Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic β-islets. FEBS J. 278(7), 1167-1174 (2011).
44. Joglekar MV, Patil D, Joglekar VM et al. The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets 1(2), 137-147 (2009).
45. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 58(5), 1050-1057 (2009).
46. Fred RG, Bang-Berthelsen CH, Mandrup-Poulsen T, Grunnet LG, Welsh N. High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression. PLoS ONE 5(5), e10843 (2010).
47. Poy MN, Hausser J, Trajkovski M et al. miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc. Natl Acad. Sci. USA 106(14), 5813-5818 (2009).
48. Zampetaki A, Kiechl S, Drozdov I et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in Type 2 diabetes. Circ. Res. 107(6), 810-817 (2010).
49. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 12(8), 1161-1191 (2011).
50. Caporali A, Meloni M, Völlenkle C et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123(3), 282-291 (2011).
51. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28(11), 570-579 (2010).
52. Sutherland JE, Costa M. Epigenetics and the environment. Ann. NY Acad. Sci. 983, 151-160 (2003). (Pubitemid 36399328)
53. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 308(5727), 1466-1469 (2005). Erratum in: Science 328(5979), 690 (2010). (Pubitemid 40791300)
54. Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat. Genet. 23(3), 314-318 (1999). (Pubitemid 29526429)
55. Meaney MJ. Maternal care, gene expression and the transmission of individual differences in stress reactivity across generations. Ann. Rev. Neurosci. 24, 1161-1192 (2001). (Pubitemid 32695257)
56. Francis DD, Meaney MJ. Maternal care and the development of stress responses. Curr. Opin. Neurobiol. 9(1), 128-134 (1999). (Pubitemid 29084099)
57. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7(8), 847-854 (2004). (Pubitemid 38989508)
58. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102(30), 10604-10609 (2005). (Pubitemid 41061601)
59. McGowan PO, Sasaki A, D'Alessio AC et al. Epigenetic regulation of glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 12(3), 342-348 (2009).
60. Philibert R, Madan A, Andersen A, Cadoret R, Packer H, Sandhu H. Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(1), 101-105 (2007). (Pubitemid 46122645)
61. Philibert RA, Sandhu H, Hollenbeck N, Gunter T, Adams W, Madan A. The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(5), 543-549 (2008). (Pubitemid 351961655)
62. Beach SR, Brody GH, Todorov AA, Gunter TD, Philibert RA. Methylation at SLC6A4 is linked to family history of child abuse: an examination of the Iowa Adoptee sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(2), 710-713 (2010).
63. Barrès R, Osler ME, Yan J et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab. 10(3), 189-198 (2009).
64. Strakovsky RS, Zhang X, Zhou D, Pan YX. Gestational high fat diet programs hepatic phosphoenolpyruvate carboxykinase gene expression and histone modification in neonatal offspring rats. J. Physiol. 589(Pt 11), 2707-2717 (2011).
65. Kelsall CJ, Hoile SP, Irvine NA et al. Vascular dysfunction induced in offspring by maternal dietary fat involves altered arterial polyunsaturated fatty acid biosynthesis. PLoS ONE 7(4), e34492 (2012).
66. Sandovici I, Smith NH, Nitert MD et al. Maternal diet and aging alter the epigenetic control of a promoter-enhancer interaction at the Hnf4a gene in rat pancreatic islets. Proc. Natl Acad. Sci. USA 108(13), 5449-5454 (2011).
67. Zheng S, Rollet M, Pan YX. Protein restriction during gestation alters histone modifications at the glucose transporter 4 (GLUT4) promoter region and induces GLUT4 expression in skeletal muscle of female rat offspring. J. Nutr. Biochem. 23(9), 1064-1071 (2012).
68. Zheng S, Rollet M, Pan YX. Maternal protein restriction during pregnancy induces CCAAT/enhancer-binding protein (C/EBPβ) expression through the regulation of histone modification at its promoter region in female offspring rat skeletal muscle. Epigenetics 6(2), 161-170 (2011).
69. Jousse C, Parry L, Lambert-Langlais S et al. Perinatal undernutrition affects the methylation and expression of the leptin gene in adults: implication for the understanding of metabolic syndrome. FASEB J. 25(9), 3271-3278 (2011).
70. Slater-Jefferies JL, Lillycrop KA, Townsend PA et al. Feeding a protein-restricted diet during pregnancy induces altered epigenetic regulation of peroxisomal proliferator-activated receptor-α in the heart of the offspring. J. Dev. Orig. Health Dis. 2(4), 250-255 (2011).
71. Hoile SP, Lillycrop KA, Grenfell LR, Hanson MA, Burdge GC. Increasing the folic acid content of maternal or post-weaning diets induces differential changes in phosphoenolpyruvate carboxykinase mRNA expression and promoter methylation in rats. Br. J. Nutr. 108(5), 852-857 (2012).
72. Burdge GC, Hoile SP, Lillycrop KA. Epigenetics: are there implications for personalised nutrition? Curr. Opin. Clin. Nutr. Metab. Care 15(5), 442-447 (2012).
73. Roseboom TJ, van der Meulen JH, Ravelli AC, Osmond C, Barker DJ, Bleker OP. Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview. Mol. Cell Endocrinol. 185(1-2), 93-98 (2001). (Pubitemid 33103957)
74. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad. Sci. USA 105(44), 17046-17049 (2008).
75. Tobi EW, Lumey LH, Talens RP et al. DNA methylation differences after exposure to prenatal famine are common and timing-and sex-specific. Hum. Mol. Genet. 18(21), 4046-4053 (2009).
76. Ravelli AC, van der Meulen JH, Michels RP, Osmond C, Barker DJ, Hales CN, Bleker OP. Glucose tolerance in adults after prenatal exposure to famine. Lancet 351(9097), 173-177 (1998). (Pubitemid 28037007)
77. Talens RP, Jukema JW, Trompet S et al. Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction. Int. J. Epidemiol. 41(1), 106-115 (2012).
78. Pembrey ME, Bygren LO, Kaati G et al. Sex-specific, male-line transgenerational responses in humans. Eur. J. Hum. Genet. 14(2), 159-166 (2006). (Pubitemid 43135858)
79. Godfrey KM, Sheppard A, Gluckman PD et al. Epigenetic gene promoter methylation at birth is associated with child's later adiposity. Diabetes 60(5), 1528-1534 (2011).
80. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N. Engl. J. Med. 336(18), 1269-1275 (1997). (Pubitemid 27187779)
81. Barrès R, Yan J, Egan B et al. Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab. 15(3), 405-411 (2012).
82. Rönn T, Volkov P, Davegårdh C et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 9(6), e1003572 (2013).
83. Nitert MD, Dayeh T, Volkov P et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with Type 2 diabetes. Diabetes 61(12), 3322-3332 (2012).
84. Barres R, Kirchner H, Rasmussen M et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep. 3(4), 1020-1027 (2013).
85. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 159(8), 543-551 (2013).
86. Johnson M, Jones R, Freeman C et al. Can diabetes prevention programmes be translated effectively into real-world settings and still deliver improved outcomes? A synthesis of evidence. Diabet. Med. 30(1), 3-15 (2013).
87. Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics 10(7), 1067-1076 (2009).
88. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. Human CYP2E1 is regulated by miR-378. Biochem. Pharmacol. 79(7), 1045-1052 (2010).
89. Devlin AH, Thompson P, Robson T, McKeown SR. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation. Mol. Carcinog. 49(2), 190-199 (2010).
90. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos. 37(10), 2112-2117 (2009).
91. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66(18), 9090-9098 (2006). (Pubitemid 44521128)
92. Suter M, Abramovici A, Showalter L et al. In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. Metabolism 59(10), 1481-1490 (2010).
93. Zierath JR, Barrès RE. Nutritional status affects the epigenomic profile of peripheral blood cells. Epigenomics 3(3), 259-260 (2011).
94. Semiz S, Dujic T, Causevic A. Pharmacogenetics and personalized treatment of Type 2 diabetes. Biochem. Med. (Zagreb) 23(2), 154-171 (2013).
95. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92(4), 437-439 (2012).